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Purpose: The aim of this pilot study was to test the hypothesis that myocardial ischemia 
  complicates the management of some patients with chest-pain-free chronic obstructive   pulmonary 
disease (COPD) exacerbations.
Methods: In this prospective, observational, cohort study, patients admitted to a 350-bed com-
munity teaching hospital, with dyspnea and a primary diagnosis of COPD exacerbation, were 
followed for enzymatic and electrocardiographic evidence of myocardial ischemia for the first 
24 hours of hospital admission.
Results: A total of 114 patients were studied. Overall, four patients had definite myocardial 
infarctions, one had definite myocardial ischemia and 14 had possible myocardial ischemia. 
In multiple logistic regression models, age, number of coronary risk factors, and amount of 
administered albuterol were not associated with myocardial injury.
Conclusion: While unrecognized myocardial injury is relatively rare in patients with an exac-
erbation of COPD, it occurs frequently enough to warrant some caution since   beta-agonists are 
the mainstays of therapy.
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Introduction
Distinguishing dyspnea caused by heart versus lung disease has long been recognized 
as a very difficult task for chest and emergency physicians.1 Patients with chronic 
obstructive pulmonary disease (COPD) often present to hospital with acute dyspnea. 
These patients often have co-existent risks for – or established – coronary heart dis-
ease (CHD), which may mimic dyspnea related to COPD. The Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) highlights that the population of patients 
with COPD also has common pathway comorbidities (ischemic heart disease and lung 
cancer); complicating comorbidities (pulmonary hypertension and heart failure); and 
coincidental or intercurrent comorbidities (eg, infections, dementia, depression), that 
may contribute substantially to acute or chronic illness.2
Since treatment of COPD exacerbations includes aerosolized beta-agonists that can 
exacerbate CHD, it is incumbent on clinicians to detect dyspnea due to CHD versus 
COPD, to properly treat dyspnea. In a preliminary review of medical records, we reported 
that 26 of 27 patients discharged with a primary diagnosis of myocardial infarction (MI) 
and secondary diagnosis of COPD, who presented to our emergency department with 
dyspnea but not chest pain, had troponin-T elevations in the first 24 hours of their stay.3 
Since not all COPD patients with acute dyspnea but no chest discomfort receive elec-
trocardiographic (ECG) and enzymatic follow-up to rule-out acute coronary syndrome, International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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we reasoned that some patients with cardiac-related dyspnea 
could be escaping detection. In this prospective study, we 
hypothesized that some patients with COPD presenting to 
hospital with dyspnea ascribed to COPD exacerbation, have 
unrecognized active CHD as the cause, or develop secondary 
CHD complicating their management.
Methods
study design and subjects
This prospective cohort study was conducted after approval by 
the investigational review committee of Bridgeport   Hospital, 
a 350-bed community teaching hospital affiliated with the 
Yale New Haven Health System. The Hospital Board waived 
requiring informed consent of patients owing to the   minimal 
risk to patients. All patients aged greater than 50 years 
who were admitted to the hospital medical wards with the 
complaint of dyspnea, attributed by   emergency department 
physicians to COPD   exacerbation, from   September 30th 
2008 to April 30th 2009, were eligible for inclusion. Patients 
were excluded if they: 1) had chest pain; 2) were admitted for 
comfort care only; and/or 3) were admitted for “ruling out” 
acute coronary syndrome. All patients met GOLD criteria for 
COPD exacerbation, namely “an event in the natural course 
of the disease characterized by a change in the patient’s 
baseline dyspnea, cough and/or sputum that is beyond normal 
day-to-day variations, is acute in onset, and may warrant a 
change in regular medication in a patient with underlying 
COPD”.2 All patients carried a clinical diagnosis of COPD 
and were receiving outpatient treatments for COPD before 
hospital admission.
For patients with more than one hospitalization during the 
study period, data from only the first admission were included 
in analysis. Patients’ caregivers, who provided all clinical 
management, were encouraged to order serum troponin-T and 
electrocardiograms on admission and 8–24 hours   following 
admission.
Data collection
Demographic and clinical data were abstracted from   medical 
records and included age, gender, race, co-morbidities, 
previous cardiac history, medications (before and during 
admission), laboratory data, and admission chest   radiograph 
interpretations. Sequential ECGs of patients during the 
first 24 hours of admission (and prior to admission, when 
  available) were interpreted in blinded fashion by a board-
certified cardiologist (SZ). After examining ECGs, the car-
diologist was given corresponding troponin and same-day 
creatinine values and, applying consensus-based definitions,4 
rendered diagnoses of: definite MI (when both ECG and 
enzymes were definitive); ischemia (ECG   definitive with 
normal enzymes); possible ischemia (nonspecific ECG 
changes with normal troponins, or normal ECG with slightly 
elevated troponins in the presence of renal disease); or not 
MI or ischemia. A troponin value .0.10 ng⋅mL-1 (in the 
absence of elevated serum creatinine) is considered abnormal 
in our laboratory and was required for designating definite 
or possible MI.
Records of patients with definite or possible cardiac 
injury were examined in greater detail to ascertain whether 
they had any 6-dermatome symptoms (chest pain/pressure, 
shoulder pain, left arm pain, etc) either before or in the first 
24 hours of admission.
statistical analyses
Non-normally distributed variables are reported as median 
and interquartile ranges. Categorical variables are reported as 
percentages of total numbers of patients and comparisons are 
made using chi-square tests. The primary outcome of interest 
is the proportion of patients who suffer myocardial injury. 
Demographic and clinical data of these patients were com-
pared to patients who had no evidence of myocardial infarction 
or ischemia. Logistic regression analyses were used to deter-
mine independent predictors of myocardial injury. Variables 
found to be significantly associated with   myocardial injury 
in univariate analyses and those with biological plausibility 
were included in stepwise, backward elimination, multiple 
logistic regression models. Analyses were performed using 
Stata 9 software (StataCorp, College Station, TX). A two tailed 
P-value of ,0.05 was considered statistically significant.
Results
A total of 114 patients were studied. Patients averaged   
72.5 years (median 73 years; range 50–95 years); 59% of 
114 patients were female; and 70% were caucasian (see Table 1). 
All patients had two or more (mean 4 ± 1.4) coronary risk fac-
tors and received an average of 14.3 mg of aerosolized albuterol 
in the first 24 hours of treatment. Seventy patients had both 
initial and follow-up ECGs and troponin measurements; 76 had 
more than only one ECG; 99 had more than one troponin mea-
surement; and 15 had only one troponin measurement. Overall, 
four patients had definite MI, one had definite ischemia, and 
14 had possible ischemia. In the four patients with definite 
MI, sequential troponin   values were 0.02, 0.14; 0.56, 0.53; 
0.01, 0.60; and 0.14, 0.10 ng⋅mL-1 (see Figure 1). One patient 
with definite ischemia had   sequential troponin values of 0.01, 
0.09 ng⋅mL-1. Two patients with possible ischemia had values International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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of 1.16, 1.19 and 0.11, 0.11 ng⋅mL-1. Thirty out of 53 patients 
who had BNP levels measured on admission had elevated lev-
els (.900 pg⋅mL-1). In both univariate analyses and multiple 
logistic   regression models, age, number of coronary risk   factors, 
chest radiographic consistent with   congestive heart failure, and 
amount of   administered albuterol were not   associated with isch-
emia. Kidney dysfunction (  creatinine .1.2 mg⋅dL-1), however, 
was significantly   associated with ischemia in both univariate 
analyses (see Table 1) and multivariate modeling (OR = 4.3; 
95% CI: 1.2–15.3).
Discussion
To our knowledge, this is the first study to examine the rate 
at which unrecognized CHD either causes or complicates 
Number of patients (n = 114)
Positive troponin Possible ischemia Definite ischemia Definite MI
16 11 16 21 23 1341 45 1561 67 178 1891 91 01 0 111
Figure 1 enzymatic and/or electrocardiographic evidence of myocardial injury (MI).
Table 1 Characteristics of studied patients*
Variable Total   Ischemia/MI 
n (%)
Nonischemia/MI 
n (%)
P-value
n = 114 19 (17) 95 (83)
Mean age (sD) in years 72.5 (10) 74.9 (10) 72.1 (10) 0.27
gender
  Female
  Male
 
67 
47
 
12 (18) 
7 (15)
 
55 (82) 
40 (85)
 
 
0.67
race
  White
  nonwhite
 
80 (70) 
34 (30)
 
14 (18) 
5 (15)
 
66 (83) 
29 (85)
 
 
0.71
Mean number of coronary artery disease risk factors 4.1 4.2 4.1 0.67
Comorbidities
number of comorbidities 4.3 4.4 4.2 0.67
Diabetes mellitus 27 6 (78) 21 (22) 0.38
hypertension 66 9 (14) 57 (86) 0.31
Obesity 50 11 (22) 39 (78) 0.18
Coronary artery disease 22 4 (18) 18 (82) 0.83
hypercholesterolemia 28 4 (14) 24 (86) 0.70
Vital signs
heart rate on admission (beats/min) 94 93 95 0.77
respiratory rate (breaths/min) 23 25 23 0.10
systolic blood pressure on admission (mmhg) 137 141 136 0.49
Diastolic blood pressure on admission (mmhg) 79 79 79 0.96
Creatinine (mg/dL) 0.95 1.19 0.90 0.01**
Cumulative albuterol (mg) 14.3 15.1 14.1 0.72
hospital length of stay (d) 7.6 6.3 7.8 0.60
Notes: *All patients had a positive smoking history. **P < 0.05.
Abbreviations: sD, standard deviation. International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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the clinical course of COPD patients presenting to hospital 
with a complaint of dyspnea but no other symptoms of acute 
coronary syndrome. While the frequency of “definite” events 
was low (4%), an additional 11% had ECG and/or   enzymatic 
evidence that was suggestive of myocardial injury. As serial 
ECGs and troponin determinations were not   completed in all 
patients, this figure may underestimate the true   prevalence. 
Even if only 4% of the over 700,000 patients   admitted 
to   hospital with COPD exacerbation each year5 have 
  unrecognized myocardial injury, since such patients routinely 
receive beta-agonist therapy, this subset is at particular risk 
of unintended iatrogenic injury.6,7
COPD is a chronic inflammatory disease that promotes 
atherogenesis and CHD.8 During acute exacerbations, hypox-
emia and stress associated with increased work of breathing 
may promote sympathetic overactivity9 that increases myo-
cardial oxygen demand. Accordingly, myocardial ischemia 
and left ventricular dysfunction, which itself can promote 
wheezing, may complicate or be mistaken for an exacerbation 
of COPD. Our study cannot decipher whether ischemia is the 
primary reason for dyspnea, or a stress-related complication 
that contributes to dyspnea in this vulnerable cohort.
In a preliminary retrospective analysis, we reported that 
29% of 94 patients with COPD discharged with a primary 
diagnosis of myocardial infarction, presented to hospital 
with dyspnea but no chest pain. Of these, 26 of 27 had tro-
ponin elevations in the first 24 hours of hospitalization and 
a   majority (62%) received beta-agonists aerosol therapies.3 
Harvey and Hancox10 reported that 58 of 235 patients admitted 
to hospital with an exacerbation of COPD, who had troponin 
levels measured, had an elevated troponin. Seven of these 
were categorized as myocardial infarction. It is possible that 
troponin elevations associated with acute exacerbations of 
COPD arise from right heart strain associated with   pulmonary 
hypertension.11 Additionally, even troponin elevations   during 
COPD exacerbations do not necessarily connote classic 
acute coronary syndrome (ACS), since stress-related and/or 
therapeutically administered catecholamines may promote 
Tako-Tsubo phenomenon.12
Our study has a number of notable limitations. Firstly, the 
study protocol did not mandate that serial troponins and electro-
cardiograms be obtained for all patients. So, while 114 patients 
were studied, only 70 had sufficient data to   determine whether 
they had myocardial injury. It is thus   possible (or even likely, 
since those with chest pain thought to be coronary syndrome 
were excluded) that this study systematically underestimates 
the rate of cardiac ischemia   complicating COPD   exacerbation. 
Secondly, emergency   physicians were aware of the study 
and its theoretical   underpinnings and thus could have more 
vigorously scrutinized patients with COPD and CHD for 
ACS. This might also result in systematic underestimation 
of CHD complicating COPD. Cause and effect relationships 
cannot be inferred with our methodology. Additionally, the 
study is likely underpowered to detect potentially important 
pathophysiologic relationships (eg, albuterol dose and myo-
cardial ischemia). Since inclusion was predicated on clinical 
grounds and not all patients had pulmonary function tests, it 
is possible that not all had COPD (despite being treated as 
outpatients for this diagnosis). Finally, there is no absolute 
gold standard for diagnosing myocardial ischemia in this 
population of patients. Patients with classic ACS symptoms 
were excluded, leaving only enzymatic and ECG evidence 
(European Society of Cardiology and American College of 
Cardiology criteria) for diagnosis. Electrocardiography in this 
demographic is highly nonspecific: while 11% had ECG signs 
that could connote ischemia, only 4% demonstrated either 
definitive changes or evolution with time to allow categoriza-
tion of definite ischemia or non-ST elevation MI. Similarly, 
troponin values are highly sensitive but not very specific for 
detection of myocardial infarction in patients without classic 
ACS. Accordingly, we cannot exclude the possibility of some 
false positive results. Some bias could also have affected 
results, since emergency personnel were encouraged to obtain 
ECGs and troponins on patients in whom they previously had 
low (or no) clinical suspicion for ACS; we cannot discount the 
possibility that some patients were admitted with a primary 
diagnosis of myocardial injury as a result of our study. Since 
even mild renal dysfunction was independently associated 
with possible or definite myocardial injury, it is possible that 
some elevated troponins were “false positives”, ie, not indica-
tive of acute injury. Nonetheless, insofar as only two patients 
had isolated elevated troponin values (see Figure 1), this would 
impact our results minimally as renal dysfunction does not 
account for misclassification of ECGs. While a conserva-
tive interpretation of our results suggests only 4% of COPD 
patients presenting with dyspnea have either primary cardiac 
ischemia or cardiac ischemia   complicating   management, an 
additional 11% of patients had ECG evidence that could rep-
resent myocardial injury. Another weakness is that we did not 
ascertain the rate of myocardial ischemia in matched controls 
without COPD. But to the extent that otherwise clinically 
silent cardiac events may be “missed”, this finding carries 
implications for management of between 4% and 15% of the 
over 700,000 patients each year who are hospitalized with 
COPD exacerbation, especially since beta-agonist aerosols 
may promote or exacerbate   cardiac ischemia.6,7International Journal of COPD
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In conclusion, this study demonstrates that ECG and 
enzymatic evidence of myocardial injury is relatively uncom-
mon in patients presenting with acute exacerbations of COPD. 
Nonetheless, since beta-agonists are relatively contraindicated 
in patients with active cardiac ischemia, clinicians should be 
aware that a small subset of patients with COPD   exacerbation 
may have primary or secondary cardiac ischemia that contrib-
utes to their dyspnea. Prospective studies that include patients 
with an acute exacerbation of (objectively-verified) COPD,2 
and complete data (ie, serial ECG, troponin, and symptoms) 
would be required to definitively determine the frequency and 
clinical impact of this problem.
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